Form 4: Denali Therapeutics Director Vicki L Sato Reports Sale of Shares
SEC Form 4 Filing
Director Vicki L Sato reported selling 3,080 shares of Denali Therapeutics Inc. on January 2, 2025, at a weighted average price of $20.91.
Summary
- On January 2, 2025, Vicki L Sato, a director of Denali Therapeutics Inc., sold 3,080 shares of common stock.
- The sale was executed at a weighted average price of $20.91 per share.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 21, 2024.
- Following the transaction, Sato beneficially owns 107,976 shares, including 5,967 unvested RSUs.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock sale by a company director. It doesn't inherently convey positive or negative sentiment, as it's simply a report of a transaction.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency to investors regarding the trading activities of company insiders.
Stakeholder Impact
- The sale of shares by a director could have a minor impact on shareholder sentiment, but is unlikely to be significant given the relatively small number of shares sold and the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 2024-03-21 | Adoption date of the Rule 10b5-1 trading plan |
| 2025-01-02 | Date of the stock sale transaction |
| 2025-01-03 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.